X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dr. Reddys with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs MYLAN (US) - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DR. REDDYS LAB   MYLAN
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-17
MYLAN
Dec-14
DR. REDDYS LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,3973,805-   
Low Rs2,5602,682-   
Sales per share (Unadj.) Rs856.51,302.8-  
Earnings per share (Unadj.) Rs78.0156.9-  
Cash flow per share (Unadj.) Rs139.9252.6-  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs739.8647.6-  
Shares outstanding (eoy) m165.74378.37-   
Bonus/Rights/Conversions BBOI-  
Price / Sales ratio x3.52.5 139.7%   
Avg P/E ratio x38.220.7 184.8%  
P/CF ratio (eoy) x21.312.8 165.8%  
Price / Book Value ratio x4.05.0 80.4%  
Dividend payout %25.70-   
Avg Mkt Cap Rs m493,6321,227,273 40.2%   
No. of employees `00022.725.0 90.7%   
Total wages/salary Rs m31,0680-   
Avg. sales/employee Rs Th6,259.019,716.9 31.7%   
Avg. wages/employee Rs Th1,369.80-   
Avg. net profit/employee Rs Th569.72,375.2 24.0%   
INCOME DATA
Net Sales Rs m141,961492,922 28.8%  
Other income Rs m1,715-2,873 -59.7%   
Total revenues Rs m143,676490,049 29.3%   
Gross profit Rs m24,722122,592 20.2%  
Depreciation Rs m10,26636,203 28.4%   
Interest Rs m63421,262 3.0%   
Profit before tax Rs m15,53762,254 25.0%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m3490-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,9652,618 113.3%   
Profit after tax Rs m12,92159,381 21.8%  
Gross profit margin %17.424.9 70.0%  
Effective tax rate %19.14.2 453.8%   
Net profit margin %9.112.0 75.6%  
BALANCE SHEET DATA
Current assets Rs m96,837433,344 22.3%   
Current liabilities Rs m84,199338,788 24.9%   
Net working cap to sales %8.919.2 46.4%  
Current ratio x1.21.3 89.9%  
Inventory Days Days7378 94.0%  
Debtors Days Days98107 91.0%  
Net fixed assets Rs m102,552114,036 89.9%   
Share capital Rs m82917,431 4.8%   
"Free" reserves Rs m121,7920-   
Net worth Rs m122,621245,031 50.0%   
Long term debt Rs m5,449366,052 1.5%   
Total assets Rs m218,165986,961 22.1%  
Interest coverage x25.53.9 649.4%   
Debt to equity ratio x01.5 3.0%  
Sales to assets ratio x0.70.5 130.3%   
Return on assets %6.28.2 76.0%  
Return on equity %10.524.2 43.5%  
Return on capital %12.913.6 94.7%  
Exports to sales %54.60-   
Imports to sales %9.40-   
Net fx Rs m55,3150-   
CASH FLOW
From Operations Rs m21,44464,795 33.1%  
From Investments Rs m-18,404-51,099 36.0%  
From Financial Activity Rs m-3,692-17,073 21.6%  
Net Cashflow Rs m-1,144-3,378 33.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.85 Rs / USD

Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare DR. REDDYS LAB With: DIVIS LABORATORIES  ALEMBIC LTD  UNICHEM LAB  CADILA HEALTHCARE  GSK PHARMA  



Today's Market

Market at Record Highs; Strong ITC & RIL Performance & Other Top Cues to Sway the Market Today(Pre-Open)

Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services. At the closing bell last week.

Related Views On News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jan 19, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS